Navigation Links
Quantitation of Digoxin in Human Plasma Using Negative Ion Electrospray Ionization LC/MS

D. Garteiz, S. Din, and R. Morrow
TexMS Analytical Services, Houston, TX

Introduction

A Varian 1200L LC/MS/MS system was used for quantitative measurement down to 15 picograms of the cardiac glycoside, Digoxin, in human plasma using Electrospray Ionization (ESI)-LC/MS in the negative ion detection mode. Since cardiac glycosides are very thermally labile, ESI is preferred over a hot vaporization process like APCI.

Digoxin is classified as a digitalis drug and is used to treat congestive heart failure and heart rhythm irregularities. Digoxins mode of action is to strengthen the force of the heart contractions, and thus help to regulate the rate and rhythm of the heartbeat. The therapeutic level of Digoxin in human serum is 0.5 - 2.0 ng/mL with toxicity starting at 4.0 ng/mL. Because of Digoxins high potency, doses are administered from 0.125 mg to a maximum of 0.5 mg, once a day. Periodic plasma level measurements are critical for establishing the proper dose administration. The onset of action from administration is from 30 minutes to two hours and when combined with the low dosing regime, plasma levels are expected to be in the low picogram to low nanogram levels. These low picogram levels are easily detected with a Varian 1200L LC/MS system in ESI negative mode.

Instrumentation

Varian 1200L LC/MS equipped with ESI source Materials and Reagents

Digitoxin ordered from Sigma-Aldrich Corp.,Catalog Number D5878

Digoxin ordered from Sigma-Aldrich Corp.,Catalog Number D6003

Ammonium trifluoroacetate (ATFA) Sigma-Aldrich Corp.,Catalog Number D23873-2

All other chemicals are reagent grade or HPLC grade

Sample Preparation

A 1.0 mL of human plasma containing Digoxin is spiked with Digitoxin as the internal standard (Figure 1) . The plasma is made basic and both drugs are extracted using methyl-t-butyl ether. After separation of the phases by centrifugation, the organic layer is transferred into a conical tube and evaporated to dryness. The residue is then reconstituted in 40 μL of 70:30 (v:v) water:acetonitrile. A 10 μL aliquot is analyzed by ESI-LC/MS using Selected Ion Monitoring (SIM) in the negative ion mode. The mass spectrometer is set to monitor the trifluoroacetate adduct ions (ATFA)- for Digoxin at m/z 894 and Digitoxin at m/z 878.

Results and Discussion

A comparison of the LC/MS traces obtained for the Upper Limit of Quantitation (ULOQ) and Lower Limit of Quantitation (LLOQ) are shown in Figures 2 and 3. Visual examination of the chromatograms shows that no interfering peaks are present at the retention time for Digoxin. Visual examination of calibration curve for Digoxin in Figure 4 shows that excellent linearity was achieved using the weighted Linear Quadratic (1/x) model for calibration curve calculations.

During method validation, the percent recovery for Digoxin was determined to be approximately 60%. A 10 μL aliquot from a total of 40 μL of a reconstituted solution for each study sample was injected on the column. Due to limited sample recovery and using only a portion of the total recovered sample, the actual amount of Digoxin injected on-column for the lowest calibration point is 15 picograms. The Varian 1200L LC/MS easily detected Digoxin at the 15 picogram level.

Conclusion

The data obtained with the Varian 1200L LC/MS demonstrates the following:

1. Excellent linearity of response is achieved for the quantitation of Digoxin from 100 pg/mL to 5 ng/mL.

2. Excellent sensitivity can be achieved using negative ion detection for Digoxin.

3. These extremely labile glycosides do not d ecompose at the source temperatures used in this assay (200 0C). The Varian 1200L LC/MS source assembly and metal capillary design eliminates hot spots where degradation of thermally labile compounds could take place.

Reference

1. Guidance for Industry: Bioanalytical Method Validation, FDA (May 2001).

.


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Quantitation of Cabergoline at Extremely Low Plasma Concentrations with a Triple Quadrupole Mass Spectrometer
2. Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine in Bovine Plasma using the TSQ Quantum Mass Spectrometer
3. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
4. Comparison of Different Methods of mRNA Quantitation
5. Quantitation of DNA for Automated Sequencing Using the VersaFluor Fluorometer
6. Quantitation of RNA for Hybridization Blots Using the VersaFluor Fluorometer
7. Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A
8. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
9. Benchmark Plus Microplate Reader: Quantitation of Protein Concentration Using Two Different Colorimetric Assay Kits, Rev A
10. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
11. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/16/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the ... for triple negative breast cancer (TNBC), announced today their completion ... program. The YEi Start in France ... grow their business in France and ... to complete an intensive one week immersion in ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
(Date:2/16/2017)... , ... February 16, 2017 ... ... Molecular Research Inc. has further extended its industry leading Biochemistry Services specifically ... offers state-of-the-art cGMP techniques and methods for the biochemical and biosimilar ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
Breaking Biology News(10 mins):